Trial
NCT02088060
A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Central Institute of Mental Health, Mannheim
Collaborators
Martin-Luther-Universität Halle-Wittenberg; Heidelberg University; Technical University of Munich; Ludwig-Maximilians - University of Munich; Glostrup University Hospital, Copenhagen
Condition
Schizophrenia
Intervention
Cannabidiol
Why stopped
Following the expiry of the original research grant, no follow-up financing could be provided to complete the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-27